ST Pharm Co Ltd
KOSDAQ:237690
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60 400
117 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
ST Pharm Co Ltd
Net Income (Common)
ST Pharm Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Net Income (Common)
₩32.4B
|
CAGR 3-Years
104%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Net Income (Common)
₩1T
|
CAGR 3-Years
45%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Net Income (Common)
-₩164m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Net Income (Common)
-₩8.7B
|
CAGR 3-Years
19%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Net Income (Common)
-₩2.9B
|
CAGR 3-Years
58%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
9%
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Net Income (Common)
-₩8.7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
ST Pharm Co Ltd
Glance View
ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.
See Also
What is ST Pharm Co Ltd's Net Income (Common)?
Net Income (Common)
32.4B
KRW
Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Net Income (Common) amounts to 32.4B KRW.
What is ST Pharm Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
104%
Over the last year, the Net Income (Common) growth was 181%. The average annual Net Income (Common) growth rates for ST Pharm Co Ltd have been 104% over the past three years .
You don't have any saved screeners yet
